On the basis of the strategic cooperation framework agreement signed by the company in February 22nd with the Shenzhen national infectious disease clinical medical research center (hereinafter referred to as the “National Research Center”) and the third people’s Hospital of Shenzhen (referred to as the “three municipal hospitals”) in March 11th, and the binding letter of intent signed in March 11th, the company signed a formal agreement on technology development cooperation with the National Research Center and the Third Municipal Hospital, according to the announcement of Hybio Pharmaceutical Co.Ltd(300199) 418. It is intended to cooperate in the research and development of household New Coronavirus antigen detection kit. The research foundation includes, but is not limited to, existing numbered antibodies and their patents, as well as various technologies, products and patents related to the development of kit products.
According to the announcement, the covid-19 test kit has recently passed the test of China food and drug identification and Research Institute. At the same time, Hybio Pharmaceutical Co.Ltd(300199) has signed a clinical research contract with Shenzhen Third Hospital, and the clinical trial will be carried out after the clinical filing is completed. There is uncertainty about the future clinical progress and whether it can be approved for listing in the future.
Hybio Pharmaceutical Co.Ltd(300199) indicates that as of September 30, 2021, the company’s book monetary capital balance is 215 million yuan, and the asset liability ratio is 58.65%. In view of the large capital demand in the existing research projects, if the credit policy and the smoothness of financing channels change, the company may bear a certain capital risk. Please pay attention to the investment risk.
